T1	Participants 101 157	women with ErbB2 overexpressing metastatic breast cancer
T2	Participants 232 333	patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC)
T3	Participants 569 597	women with HER2-positive MBC
T4	Participants 648 675	eligible patients (N = 112)
T5	Participants 1850 1887	patients with HER2-overexpressing MBC
